Welcome to our dedicated page for Exact Sciences SEC filings (Ticker: EXAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Exact Sciences Corp (NASDAQ: EXAS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Exact Sciences’ cancer screening and diagnostic testing business, financial performance, and significant corporate events.
For EXAS, key filings include current reports on Form 8-K that describe material developments. One Form 8-K reports quarterly financial results, including revenue contributions from the Screening grouping, which encompasses Cologuard tests and PreventionGenetics, and from the Precision Oncology grouping, which includes global Oncotype DX and therapy selection tests. These filings also discuss non‑GAAP metrics such as adjusted EBITDA, adjusted gross margin, and free cash flow, along with reconciliations and management’s rationale for using these measures.
Another important 8-K details the Agreement and Plan of Merger among Exact Sciences, Abbott Laboratories, and a wholly owned Abbott subsidiary. This filing explains the structure of the proposed merger, the per‑share cash consideration to be paid for Exact Sciences common stock, the treatment of equity awards, the conditions to closing, termination rights, and any potential termination fee. It also notes that Exact Sciences’ board of directors unanimously approved the merger agreement and recommends that stockholders adopt it, subject to customary conditions.
Additional 8-K filings describe a collaboration and license agreement with Freenome Holdings, Inc. for blood‑based colorectal cancer screening tests, as well as other corporate announcements furnished as exhibits, such as earnings press releases and investor communications. These documents provide context on how Exact Sciences is expanding its portfolio in blood‑based screening and multi‑cancer early detection.
On Stock Titan, investors can review these SEC filings as they are made available through EDGAR. AI‑powered tools can help summarize lengthy disclosures, highlight key terms of material agreements, and surface notable changes in guidance, capital structure, or strategic direction, enabling users to quickly understand the implications of new EXAS filings.
EXACT Sciences Corp director Katherine S. Zanotti reported disposing of all her common stock in connection with the company’s acquisition by Abbott Laboratories. On March 23, 2026, Badger Merger Sub I, Inc. merged with Exact Sciences, leaving Exact as a wholly owned Abbott subsidiary.
At the merger’s effective time, each outstanding share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest. Zanotti’s 55,361 shares, plus an additional 5,398 shares, were cancelled and converted into the cash merger consideration, leaving her with no remaining Exact Sciences holdings. All restricted shares under company plans became fully vested and were also converted into the same cash amount per share, net of any tax withholding.
EXACT SCIENCES CORP director Kimberly J. Popovits reported the disposition of her remaining common shares in connection with the company’s merger with Abbott Laboratories. On March 23, 2026, Exact Sciences became a wholly owned subsidiary of Abbott under a previously signed merger agreement.
At the effective time of the merger, each outstanding share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest. All restricted shares subject to vesting or other restrictions were deemed fully vested, cancelled, and similarly converted into the cash merger consideration, leaving Popovits with no remaining Exact Sciences common stock.
Exact Sciences Corp director James Edward Doyle reported disposing of his remaining common shares in connection with the company’s merger with Abbott Laboratories. On March 23, 2026, 52,564 shares of Exact Sciences common stock were returned to the issuer, leaving 5,398 shares. A second disposition of 5,398 shares reduced his direct holdings to zero. Under the merger agreement, each Exact Sciences share outstanding at the effective time was converted into the right to receive $105.00 in cash, and restricted shares became fully vested and cancelled for the same cash consideration, less applicable tax withholding.
Exact Sciences director Paul J. Clancy disposed of his common stock in connection with the company’s cash merger with Abbott Laboratories. On March 23, 2026, he reported issuer dispositions totaling 26,038 shares of common stock, leaving him with zero shares after the transactions.
Under the merger agreement, each Exact Sciences share outstanding immediately before the effective time was converted into the right to receive $105.00 in cash, without interest. Shares of common stock that were subject to vesting or other restrictions under company stock plans were deemed fully vested at the effective time, then cancelled and converted into the same cash merger consideration, less any applicable tax withholding.
Exact Sciences Corporation director Michael J. Barber reported disposing of all his company equity in connection with the closing of a cash merger with Abbott Laboratories. At the merger’s effective time, each share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest, under the Merger Agreement.
All restricted common stock and each deferred stock unit became fully vested, then were cancelled and converted into the right to receive the same $105.00 cash consideration per underlying share, less applicable tax withholding. Barber’s Form 4 shows issuer dispositions of deferred stock units and common stock, leaving him with no remaining Exact Sciences shares or deferred stock units.
EXACT SCIENCES CORP director Leslie Trigg disposed of all her directly held common shares back to the company in connection with its cash merger with Abbott Laboratories. One transaction returned 3,244 shares and a second returned 13,925 shares, leaving her with zero shares afterward.
Under the merger terms, each Exact Sciences common share outstanding immediately before the effective time was converted into the right to receive $105.00 in cash, without interest. Stock awards subject to vesting or other restrictions were also deemed fully vested, cancelled and converted into the same cash consideration, less applicable tax withholding.
Exact Sciences Corp notified the Nasdaq Stock Market LLC of a removal of its Common Stock from listing and registration pursuant to Form 25. The exchange certified it complied with 17 CFR 240.12d2-2 and the issuer complied with exchange rules governing voluntary withdrawal.
The filing is an administrative notice of delisting/withdrawal under Section 12(b) of the Exchange Act and does not state transaction amounts, proceeds, or timing beyond the regulatory certification.
Exact Sciences Corporation has been acquired by Abbott Laboratories and is now a direct, wholly owned subsidiary of Abbott. In the merger, each share of Exact common stock (other than dissenting and certain excluded shares) was converted into the right to receive $105.00 in cash, less applicable withholding taxes, resulting in total merger consideration of approximately $21 billion.
Following the merger, Exact’s common stock will be delisted from Nasdaq, and Exact plans to deregister its shares and suspend SEC reporting. Exact also repaid in full all obligations under its 2025 credit agreement. For holders of Exact’s various convertible notes due 2027, 2028, 2030 and 2031, the merger changed each note so that each $1,000 principal amount is now convertible solely into cash equal to the applicable conversion rate multiplied by $105.00. Exact’s prior board members and officers resigned at the effective time, and its certificate of incorporation and bylaws were amended and restated.
Exact Sciences Corporation reports that all regulatory approvals and clearances needed to complete its planned merger with Abbott Laboratories have been obtained. Exact’s stockholders had previously approved the transaction at a special meeting on February 20, 2026. The merger, under which Exact will become a direct, wholly owned subsidiary of Abbott, is anticipated to close on March 23, 2026, subject to satisfaction or waiver of the remaining conditions in the merger agreement. The company also highlights typical merger-related risks, including potential delays, termination scenarios, transaction costs, business disruption, and possible litigation.
Exact Sciences President and CEO Kevin T. Conroy reported multiple equity compensation events involving restricted stock units and common stock. On February 27, 2026, several restricted stock unit awards vested, each unit representing a right to receive one share of common stock.
Upon vesting, Mr. Conroy acquired corresponding shares of common stock through derivative exercises, and the company retained blocks of 8,528, 10,419, and 13,060 shares at $103.25 per share for tax withholding purposes. After these transactions, he directly held 1,278,045 shares in various accounts and plans, plus additional indirect holdings.
A footnote states that, in addition to the common shares reported, Mr. Conroy also holds an aggregate of 737,129 vested and unvested options and restricted stock units, each unit representing a contingent right to receive one share of common stock.